Despite modern immunotherapies and existing drugs, lung cancer patients often develop resistance to treatment. To close this gap, an international team including Thekla Cordes, professor for cell metabolism at Technische Universität Braunschweig at the Braunschweig Centre for Systems Biology (BRICS) and the Helmholtz Centre for Infection Research (HZI), as well as researchers from the Salk Institute for Biological Studies (USA) and Yale University School (USA), investigated potential targets for cancer therapies.
